Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
Browsing: Amyotrophic lateral sclerosis
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
A preliminary clinical study has demonstrated that the experimental drug tofersen may be effective in the treatment of a genetic form of ALS.
Researchers have demonstrated that there may be a link between playing professional soccer and developing ALS. Soccer players studied were almost twice as likely to develop the disease than the general population.
Gene therapy for disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and Batten disease has seen success in animal models.
Researchers have revealed that RNA-binding proteins accumulate in the brains of people with non-heritable amyotrophic lateral sclerosis and frontotemporal dementia.
A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.
After careful evaluation of the ‘Right to Try ‘Act, BrainStorm have announced that it will not make NurOwn® available under this legislation at this time.
Researchers have identified genes in the human genome that could modify the severity of amyotrophic lateral sclerosis and frontotemporal dementia.
Disturbance to nuclear transport caused by protein aggregation has been implicated in the pathology of ALS and FTD.